DKK630.00
2.61% day before yesterday
Copenhagen, Dec 27, 04:59 pm CET
ISIN
DK0062266474
Symbol
GUBRA
Sector
Industry

Gubra A/S Stock price

DKK630.00
-14.00 2.17% 1M
+170.00 36.96% 6M
+505.00 404.00% YTD
+505.00 404.00% 1Y
+520.00 472.73% 3Y
+520.00 472.73% 5Y
+520.00 472.73% 10Y
Copenhagen, Closing price Fri, Dec 27 2024
+16.00 2.61%
ISIN
DK0062266474
Symbol
GUBRA
Sector
Industry

Key metrics

Market capitalization DKK10.27b
Enterprise Value DKK9.92b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 44.32
P/S ratio (TTM) P/S ratio 45.90
P/B ratio (TTM) P/B ratio 22.15
Revenue (TTM) Revenue DKK223.82m
EBIT (operating result TTM) EBIT DKK-59.07m
Free Cash Flow (TTM) Free Cash Flow DKK-44.17m
EPS (TTM) EPS DKK-2.85
P/E forward negative
P/S forward 40.07
EV/Sales forward 38.68
Show more

Is Gubra A/S a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Gubra A/S Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a Gubra A/S forecast:

2x Buy
100%

Analyst Opinions

2 Analysts have issued a Gubra A/S forecast:

Buy
100%

Financial data from Gubra A/S

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
224 224
-
100%
- Direct Costs 92 92
-
41%
131 131
-
59%
- Selling and Administrative Expenses 84 84
-
37%
- Research and Development Expense 97 97
-
43%
-49 -49
-
-22%
- Depreciation and Amortization 9.67 9.67
-
4%
EBIT (Operating Income) EBIT -59 -59
-
-26%
Net Profit -47 -47
-
-21%

In millions DKK.

Don't miss a Thing! We will send you all news about Gubra A/S directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Gubra ApS operates as biotechnology company. It engages in the business of pre-clinical contract research services and peptide-based drug discovery within metabolic and fibrotic diseases. The company operates through two business segments: CRO Services and Discovery & Partnerships. The CRO Services segment provides specialized pre-clinical contract research and development services for the pharmaceutical and biotechnology industry. The Discovery & Partnerships segment involves in discovery, design and development of peptide-based drug candidates with the aim of entering partnerships with pharmaceutical or biotechnology companies. Gubra was founded by Jacob Jelsing and Niels Vrang in 2008 and is headquartered in Horsholm, Denmark.

Head office Denmark
CEO Henrik Blou
Employees 219
Founded 2008
Website www.gubra.dk

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today